Neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, and mean platelet volume as potential biomarkers for early detection and monitoring of colorectal adenocarcinoma

European Journal of Cancer Prevention

Volumn 24, Issue 4, 2015, Pages 328-333

  Kilincalp, Serta ^a   Çoban, Şahin ^a   Akinci, Hakan ^a   Hamamc, Mevlüt ^a   Karaahmet, Fatih ^a   Coşkun, Yusuf ^a   Üstün, Yusuf ^a   Şimşek, Zahide ^a   Erarslan, Elife ^a   Yüksel, Ilhami ^a,b  

^a Department of Gastroenterology   (Turkey)

^b Yldrm Beyazt University   (Turkey)

Author keywords

biomarker; colorectal cancer; diagnose; mean platelet volume; neutrophil lymphocyte ratio; platelet lymphocyte ratio

Indexed keywords

HEMOGLOBIN; BIOLOGICAL MARKER;

ADULT; ANEMIA; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CANCER SURGERY; COLONOSCOPY; COLORECTAL CARCINOMA; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE MARKER; EARLY DIAGNOSIS; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL LYMPHOCYTE RATIO; PLATELET LYMPHOCYTE RATIO; PREOPERATIVE PERIOD; PRIORITY JOURNAL; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; THROMBOCYTE COUNT; THROMBOCYTE VOLUME; ADENOCARCINOMA; AGED; BLOOD; CASE CONTROL STUDY; COLORECTAL NEOPLASMS; CYTOLOGY; EARLY CANCER DIAGNOSIS; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; METABOLISM; MIDDLE AGED; NEUTROPHIL; PROCEDURES; RETROSPECTIVE STUDY;

ADENOCARCINOMA; AGED; BIOMARKERS; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; FEMALE; HEMOGLOBINS; HUMANS; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MALE; MEAN PLATELET VOLUME; MIDDLE AGED; NEUTROPHILS; PLATELET COUNT; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 84930753996     PISSN: 09598278     EISSN: 14735709     Source Type: Journal    
DOI: 10.1097/CEJ.0000000000000092     Document Type: Article

References (47)

1. Allison JE, Tekawa IS, Ransom LJ, Adrain AL (1996). A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med 334:155-159.
2. American Cancer Society Cancer Facts and Figures (2011-2013). Available at: http://www.cancer.org/. [Accessed 2 August 2014].
3. Ashizawa T, Okada R, Suzuki Y, Takagi M, Yamazaki T, Sumi T, et al. (2005). Clinical significance of interleukin-6 (IL-6) in the spread of gastric cancer: role of IL-6 as a prognostic factor. Gastric Cancer 8:124-131.
4. Balkwill F, Coussens LM (2004). Cancer: an inflammatory link. Nature 431:405-6.
5. Belluco C, Nitti D, Frantz M, Toppan P, Basso D, Plebani M, et al. (2000). Interleukin-6 blood level is associated with circulating carcinoembryonic antigen and prognosis in patients with colorectal cancer. Ann Surg Oncol 7:133-138.
6. Boyle P, Ferlay J (2005). Mortality and survival in breast and colorectal cancer. Nat Clin Pract Oncol 2:424-425.
7. Cho H, Hur HW, Kim SW, Kim SH, Kim JH, Kim YT, Lee K (2009). Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother 58:15-23.
8. Duffy MJ, van Dalen A, Haglund C, Hansson L, Klapdor R, Lamerz R, et al. (2003). Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. Eur J Cancer 39:718-727.
9. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (2010). American joint committee on cancer staging manual. 7th ed. New York: Springer.
10. Erlinger TP, Platz EA, Rifai N, Helzlsouer KJ (2004). C-reactive protein and the risk of incident colorectal cancer. JAMA 291:585-590.
11. Ferlay J, Parkin DM, Steliarova-Foucher E (2010). Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46:765-781.
12. Ferradini L, Miescher S, Stoeck M, Busson P, Barras C, Cerf-Bensussan N, et al. (1991). Cytotoxic potential despite impaired activation pathways in T lymphocytes infiltrating nasopharyngeal carcinoma. Int J Cancer 47:362-370.
13. Fjørtoft I, Furnes B, Hausken T, Storli KE, Eide GE, Søndenaa K (2013). Pre-operative anaemia in colon cancer patients became normal after more than a year post-operatively but did not influence oncological outcome in the final analysis. Scand J Gastroenterol 48:663-671.
14. Hu Y, Wang JL, Tao HT, Wu BS, Sun J, Cheng Y, et al. (2013). Expression and significance of TSGF, CEA and AFP in patients before and after radical surgery for colon cancer. Asian Pac J Cancer Prev 14:3877-3880.
15. Inagaki N, Kibata K, Tamaki T, Shimizu T, Nomura S (2014). Prognostic impact of the mean platelet volume/platelet count ratio in terms of survival in advanced non-small cell lung cancer. Lung Cancer 83:97-101.
16. Ishizuka M, Nagata H, Takagi K, Iwasaki Y, Kubota K (2013). Combination of platelet count and neutrophil to lymphocyte ratio is a useful predictor of postoperative survival in patients with colorectal cancer. Br J Cancer 109:401-407.
17. Karaman K, Bostanci EB, Aksoy E, Kurt M, Celep B, Ulas M, et al. (2011). The predictive value of mean platelet volume in differential diagnosis of nonfunctional pancreatic neuroendocrine tumors from pancreatic adenocarcino-mas. Eur J Intern Med 22:e95-e98.
18. Kilinçalp S, Ekiz F, Basar O, Ayte MR, Coban S, Yilmaz B, et al. (2013). Mean platelet volume could be possible biomarker in early diagnosis and monitoring of gastric cancer. Platelets[Epub ahead of print].
19. Klampfer L (2011). Cytokines, inflammation and colon cancer. Curr Cancer Drug Targets 11:451-464.
20. Knüpfer H, Preiss R (2010). Serum interleukin-6 levels in colorectal cancer patients-a summary of published results. Int J Colorectal Dis 25:135-140.
21. Kurt M, Onal IK, Sayilir AY, Beyazit Y, Oztas E, Kekilli M, et al. (2012). The role of mean platelet volume in the diagnosis of hepatocellular carcinoma in patients with chronic liver disease. Hepatogastroenterology 59:1580-1582.
22. Kusumanto YH, Dam WA, Hospers GA, Meijer C, Mulder NH (2003). Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. Angiogenesis 6:283-287.
23. Levin B, Lieberman DA, McFarland B, Andrews KS, Brooks D, Bond J, et al. American Cancer Society Colorectal Cancer Advisory Group; US Multi-Society Task Force; American College of Radiology Colon Cancer Committee (2008). Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology 134:1570-1595.
24. Mangalpally KK, Siqueiros-Garcia A, Vaduganathan M, Dong JF, Kleiman NS, Guthikonda S (2010). Platelet activation patterns in platelet size sub-populations: differential responses to aspirin in vitro. J Thromb Thrombolysis 30:251-262.
25. Morikawa T, Kato J, Yamaji Y, Wada R, Mitsushima T, Shiratori Y (2005). A comparison of the immunochemical fecal occult blood test and total colo-noscopy in the asymptomatic population. Gastroenterology 129:422-428.
26. Negrier S, Perol D, Menetrier-Caux C, Escudier B, Pallardy M, Ravaud A, et al. Groupe Francais d'Immunotherapie (2004). Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6-from the Groupe Francais d'Immunotherapie. J Clin Oncol 22:2371-2378.
27. Oge T, Yalcin OT, Ozalp SS, Isikci T (2013). Platelet volume as a parameter for platelet activation in patients with endometrial cancer. J Obstet Gynaecol 33:301-314.
28. Rex DK, Johnson DA, Anderson JC, Schoenfeld PS, Burke CA, Inadomi JM. American College of Gastroenterology (2009). American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected]. Am J Gastroenterol 104:739-750.
29. Roxburgh CS, Crozier JE, Maxwell F, Foulis AK, Brown J, McKee RF, et al. (2009). Comparison of tumour-based (Petersen Index) and inflammation-based (Glasgow Prognostic Score) scoring systems in patients undergoing curative resection for colon cancer. Br J Cancer 100:701-706.
30. Schneider MR, Hoeflich A, Fischer JR, Wolf E, Sordat B, Lahm H (2000). Interleukin-6 stimulates clonogenic growth of primary and metastatic human colon carcinoma cells. Cancer Lett 151:31-38.
31. Shimada H, Takiguchi N, Kainuma O, Soda H, Ikeda A, Cho A, et al. (2010). High preoperative neutrophil-lymphocyte ratio predicts poor survival in patients with gastric cancer. Gastric Cancer 13:170-176.
32. Sierko E, Wojtukiewicz MZ (2004). Platelets and angiogenesis in malignancy. Semin Thromb Hemost 30:95-108.
33. Simmonds PC, Primrose JN, Colquitt JL, Garden OJ, Poston GJ, Rees M (2006). Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer 94:982-999.
34. Søreide K, Nedrebø BS, Knapp JC, Glomsaker TB, Søreide JA, Kørner H (2009). Evolving molecular classification by genomic and proteomic biomarkers in colorectal cancer: potential implications for the surgical oncologist. Surg Oncol 18:31-50.
35. Spicer JD, McDonald B, Cools-Lartigue JJ, Chow SC, Giannias B, Kubes P, Ferri LE (2012). Neutrophils promote liver metastasis via Mac-1-mediated interactions with circulating tumor cells. Cancer Res 72:3919-3927.
36. Threatte GA (1993). Usefulness of the mean platelet volume. Clin Lab Med 13:937-950.
37. Tsiatas ML, Gyftaki R, Liacos C, Politi E, Rodolakis A, Dimopoulos MA, Bamias A (2009). Study of T lymphocytes infiltrating peritoneal metastases in advanced ovarian cancer: associations with vascular endothelial growth factor levels and prognosis in patients receiving platinum-based chemotherapy. Int J Gynecol Cancer 19:1329-1334.
38. Walker AS, Zwintscher NP, Johnson EK, Maykel JA, Stojadinovic A, Nissan A, et al. (2014). Future directions for monitoring treatment response in colorectal cancer. J Cancer 5:44-57.
39. Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ (2005). Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol 91:181-184.
40. Wanebo HJ, Rao B, Pinsky CM, Hoffman RG, Stearns M, Schwartz MK, Oettgen HF (1978). Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer. N Engl J Med 299:448-451.
41. Wang Y, Han G, Wang K, Liu G, Wang R, Xiao H, et al. (2014). Tumor-derived GM-CSF promotes inflammatory colon carcinogenesis via stimulating epithelial release of VEGF. Cancer Res 74:716-726.
42. Weidle UH, Klostermann S, Eggle D, Krüger A (2010). Interleukin 6/interleukin 6 receptor interaction and its role as a therapeutic target for treatment of cachexia and cancer. Cancer Genomics Proteomics 7:287-302.
43. Yamashita K, Watanabe M (2009). Clinical significance of tumor markers and an emerging perspective on colorectal cancer. Cancer Sci 100:195-199.
44. Yang SH, Lin JK, Lai CR, Chen CC, Li AF, Liang WY, Jiang JK (2004). Risk factors for peritoneal dissemination of colorectal cancer. J Surg Oncol 87:167-173.
45. Yao Y, Yuan D, Liu H, Gu X, Song Y (2013). Pretreatment neutrophil to lymphocyte ratio is associated with response to therapy and prognosis of advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy. Cancer Immunol Immunother 62:471-479.
46. Yi JH, Kim H, Jung M, Shin SJ, Choi JS, Choi GH, et al. (2013). Prognostic factors for disease-free survival after preoperative chemotherapy followed by curative resection in patients with colorectal cancer harboring hepatic metastasis: a single-institute, retrospective analysis in Asia. Oncology 85:283-239.
47. Yu H, Son GM, Joh YG (2013). The clinical significance of preoperative serum levels of carbohydrate antigen 19-9 in colorectal cancer. J Korean Surg Soc 84:231-237.